Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
24 participants
INTERVENTIONAL
2016-06-30
2018-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176760
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176890
The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects
NCT01579981
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Enteral fructose with DPP-4 inhibition
Enteral fructose + DPP-4 inhibition (sitagliptin)
After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
Tablet Sitagliptin 100mg (evening before and morning of experiments)
On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
Intestinal Fructose administration
On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
Enteral fructose without DPP-4 inhibition
Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
Intestinal Fructose administration
On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tablet Sitagliptin 100mg (evening before and morning of experiments)
On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
Intestinal Fructose administration
On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal haemoglobin concentration
* Cardiaresection with a pyloroplasty
* Informed consent
* Normal fasting plasma glucose
* Normal haemoglobin concentration
* Informed consent
Exclusion Criteria
* Disposition for diabetes mellitus
* Intestinal disease (apart from cardia resection+pyloroplasty)
* Disposition of inflammatory bowel disease
* Intestinal resection (apart from cardia resection+pyloroplasty)
* Body mass index (BMI) \> 27,5 kg/m2
* Tobacco use
* Nephropathy (se-creatinine\> 130 µM and/or albuminuria)
* Liver disease (ALAT and/or ASAT \>2 × refference value)
* known heart condition
* medicinal use, that may not be paused for 12 hours
* Obstipation
* swallowing difficulties
* previous problems with intestinal tube placement
* Latex allergy
* Fructose malabsorption
* Known diseases in the pharynx
* Previous facial or cranial fractures
* Sinusitis
* Bleeding diathesis
Matched controls:
* Cardiaresection with a pyloroplasty
* Diabetes mellitus
* Disposition for diabetes mellitus
* Intestinal disease (apart from cardia resection+pyloroplasty)
* Disposition of inflammatory bowel disease
* Intestinal resection tarmresektion (apart from cardia resection+pyloroplasty)
* Body mass index (BMI) \> 27,5 kg/m2
* Tobacco use
* Nephropathy (se-creatinine\> 130 µM and/or albuminuria)
* Liver disease (ALAT and/or ASAT \>2 × refference value)
* known heart condition
* medicinal use, that may not be paused for 12 hours
* Obstipation
* swallowing difficulties
* previous problems with intestinal tube placement
* Latex allergy
* Fructose malabsorption
* Known diseases in the pharynx
* Previous facial or cranial fractures
* Sinusitis
* Bleeding diathesis
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simon Veedfald
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Surgery C, Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Simon Veedfald, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UC/RH-vago-GLP-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.